We are a clinical-stage biopharmaceutical company committed to the development and commercialization of therapies to treat patients with a variety of ophthalmic disorders. We are currently focused on providing a novel once-daily eye drop treatment option, Nyxol®, for individuals across multiple front of the eye disorders, including night vision disturbances, glaucoma, mydriasis and presbyopia. Nyxol eye drops is an investigational 505(b)(2) drug candidate in late stage clinical development with over a decade of safety and efficacy data from Phase 1 and Phase 2 trials. Part of our strategy is to explore opportunities to acquire additional ophthalmic assets for both the front and back of the eyes, and to seek strategic partners for global commercialization.
